SCHEMBL3294684

SCHEMBL3294684

Cc1c(Cl)cccc1S(=O)(=O)Nc1cc2c(nc1OCc1ccc(Cl)c(OCCN(C)C)c1)CCCC2

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 6/20 0.39
SLC40A1 Q9NP59 1/20 0.38
HSD11B1 P28845 6/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
PIK3R1 P27986 1/20 0.33
PIK3CA P42336 1/20 0.33
AKT1 P31749 1/20 0.33
MYLK Q15746 1/20 0.33
MAPK14 Q16539 1/20 0.33
METAP2 P50579 1/20 0.33
MAPT P10636 1/20 0.33
EDNRB P24530 1/20 0.33
EDNRA P25101 1/20 0.33
HSD17B1 P14061 1/20 0.32
HSD17B2 P37059 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3290915 0.99 SLC40A1 (0.40) CCR4SLC40A1HSD11B1PTGDR2PIK3R1
SCHEMBL3298168 0.93 CCR4 (0.47) CCR4SLC40A1HSD11B1PTGDR2PIK3R1
SCHEMBL3291709 0.93 CCR4 (0.46) CCR4SLC40A1HSD11B1PTGDR2PIK3R1
SCHEMBL3296435 0.91 AKT1 (0.37) CCR4SLC40A1HSD11B1AKT1MYLK
SCHEMBL3295342 0.90 CCR4 (0.36) CCR4SLC40A1HSD11B1AKT1MYLK
SCHEMBL3296048 0.89 CCR4 (0.39) CCR4SLC40A1HSD11B1PTGDR2AKT1
SCHEMBL3294157 0.88 CCR4 (0.45) CCR4SLC40A1HSD11B1PTGDR2AKT1
SCHEMBL3293410 0.88 CCR4 (0.39) CCR4SLC40A1HSD11B1PTGDR2AKT1
SCHEMBL3291838 0.88 CCR4 (0.44) CCR4SLC40A1HSD11B1PTGDR2AKT1
SCHEMBL3292932 0.87 SLC40A1 (0.39) CCR4SLC40A1HSD11B1PTGDR2PIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100266539-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-10-21 US disclosed
US-7732442-B2 Chemokine receptor antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-06-08 US disclosed
US-20070254886-A1 Chemokine Receptor Antagonist and Medical Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-01 US disclosed
EP-1661889-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100266539-A1 CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF CCR5, CCR4, CCR1 CCR4 2/4885SLC40A1 2070/4885HSD11B1 308/4885
US-20070254886-A1 Chemokine Receptor Antagonist and Medical Use Thereof CCR5, CCR4, CCR1 CCR4 2/4885SLC40A1 2070/4885HSD11B1 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.